Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Caitlyn Fuller"'
Publikováno v:
Global Pediatric Health, Vol 4 (2017)
Children comprise one of the largest consumer groups of technology. Sleep is fundamental to optimal functioning during childhood, including health and behavior. The purpose of this study was to explore bedtime electronic use and its impact on 3 healt
Externí odkaz:
https://doaj.org/article/5e09ae48201d445ca911f22d55cb3f78
Autor:
Juan Juan Yin, Michael L. Beshiri, John B. Tucker, R. Mark Simpson, Carleen Klummp-Thomas, Holly M. Nguyen, Caitlin M. Tice, Shelley E Hoover, Lei Fang, Supreet Agarwal, Paul G. Hynes, Ross Lake, Caitlyn Fuller, Eva Corey, Rajarshi Guha, Yasmine C. Abbey, Craig J. Thomas, Keith H. Jansson, Jacob Cawley, Aian Neil Alilin, John K. Simmons, Xiaohu Zhang, Lauren E. Stahl, David A. Proia, Crystal McKnight, Kathleen Kelly
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-13 (2018)
Scientific Reports
Scientific Reports
The development of new treatments for castrate resistant prostate cancer (CRPC) must address such challenges as intrinsic tumor heterogeneity and phenotypic plasticity. Combined PTEN/TP53 alterations represent a major genotype of CRPC (25–30%) and
Publikováno v:
Journal of Adolescent Health. 62:S124-S125
Autor:
David A. Proia, Crystal Tran, Yasmine C. Abbey, Juan Juan Yin, Lauren E. Stahl, John B. Tucker, Alilin Aian Neil, Supreet Agarwal, John K. Simmons, Lei Fang, Craig J. Thomas, R. Mark Simpson, Xiahu Zhang, Jacob Cawley, Shelley B. Hoover, Michael L. Beshiri, Keith H. Jansson, Caitlyn Fuller, Holly M. Nguyen, Rajarshi Guha, Eva Corey, Paul G. Hynes, Ross Lake, Kathleen Kelly, Caitlin M. Tice
Publikováno v:
Cancer Research. 78:B018-B018
Androgen-deprivation therapy (ADT) remains the gold-standard therapy for prostate cancer (PrCa), and although ADT is initially effective, most men progress to castrate-resistant prostate cancer (CRPC) within 2-3 years. Advanced CRPC is challenging to
Autor:
Michael L. Beshiri, Holly M. Nguyen, Caitlyn Fuller, Shelley K. Hoover, Aian Neil Alilin, Juan Juan Yin, R. Mark Simpson, Xiaohu Zhang, Lauren E. Stahl, Eva Corey, Lei Fang, Supreet Agarwal, Craig J. Thomas, Crystal Tran, John K. Simmons, Rajarshi Guha, David A. Proia, Jacob Cawley, Keith H. Jansson, Paul G. Hynes, Ross Lake, Kathleen Kelly, John B. Tucker
Publikováno v:
Cancer Research. 77:3065-3065
Castrate resistant prostate cancer (CRPC) remains the primary cause of mortality for prostate cancer (PCa) patients. Several therapies are currently approved for use against CRPC, consisting mostly of androgen receptor (AR) signaling inhibitors and t
Autor:
Xiaohu Zhang, Lauren E. Stahl, Rajarshi Guha, Lei Fang, Supreet Agarwal, Paul G. Hynes, Ross Lake, Craig J. Thomas, Caitlyn Fuller, Jacob Cawley, Keith H. Jansson, Kathleen Kelly, John K. Simmons
Publikováno v:
Cancer Research. 76:LB-281
Prostate cancer (PCa) demonstrates significant intra and inter tumor heterogeneity, similar to many other solid tumors. The “gold standard” of therapy for metastatic prostate cancer is androgen deprivation therapy (ADT). Although ADT is initially